News

News and Press Releases
About the CF Foundation | NACFC | Research Cystic Fibrosis Foundation Congratulates Recipients of 2016 Research and Care Awards

At the 2016 North American Cystic Fibrosis Conference (NACFC) held on Oct. 27-29 in Orlando, Fla., the Cystic Fibrosis Foundation announced the recipients of seven awards given to members of the research and medical community whose achievements have helped advance cystic fibrosis research and care.

| 4 min read
Research CF Foundation Officially Opens One-of-a-Kind Research Lab

The lab will use the latest scientific advances -- including stem cell research and gene editing -- to accelerate new treatments for cystic fibrosis.

| 2 min read
About the CF Foundation | Research Scientists Discuss Challenges to Repair or Replace Genes at CF Research Conference

The Cystic Fibrosis Foundation invited more than 100 scientists to its research conference in Savannah, Ga., last month to discuss recent advancements in gene therapy, gene editing and stem-cell biology and how these new technologies could be applied to finding a one-time cure for cystic fibrosis.

| 3 min read
Research CFFT Funds Safety Testing of Anti-Microbial Drug to Fight Drug-Resistant Bacteria

Cystic Fibrosis Foundation Therapeutics Inc. will award up to $1.7 million to Alaxia SAS to test the safety of a potential inhaled therapy that may fight drug-resistant bacteria that infect people with cystic fibrosis

| 2 min read
Research CFFT Awards Over $4 Million to AlgiPharma

Cystic Fibrosis Foundation Therapeutics Inc. has awarded more than $4 million to AlgiPharma AS to continue Phase 2 clinical trials for a drug that may help restore normal function to cystic fibrosis mucus and make it easier for people with CF to cough out.

| 2 min read
Research CFFT Makes First Major Award to Advance Gene Editing Research in CF

Cystic Fibrosis Foundation Therapeutics Inc. announced an award of up to $5M to Editas Medicine Inc. to advance potential gene editing approaches for cystic fibrosis.

| 2 min read
Research CFFT Awards $3 million to Polyphor to Test Anti-Inflammatory Drug

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) will provide up to $3 million through a drug development award to Swiss pharmaceutical company Polyphor Ltd. to continue clinical trials of a potential anti-inflammatory drug. The drug, POL6014, inhibits the activity of an enzyme that can destroy lung tissue if produced in excess.

| 2 min read